TrialCancer chemotherapy and pharmacology2022

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship.

Kazuhiko Nakagawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.